- Products & Services
- Knowledge Base
The market for an anti-allergy lens is estimated to be over 50 million users in the US, Europe and Japan.
BOSTON, MA, March 31, 2021 /24-7PressRelease/ -- Glint Pharmaceuticals reports that Johnsons & Jonson Vision Care has received regulatory approval for a new contact lens for the delivery anti-allergy medicine to the eye. The new lens is meant to be used by contact lenses wearers who suffer from seasonal allergies. The J&J lens is called Accuvue Theravision with Ketotifen and delivers the well know antihistamine medication Ketotifen.
Glint Pharmaceuticals has also developed an anti-allergy contact lens that delivers medication over hours or days in a sustained controlled release process. The J&J lens is not based on controlled release. A controlled release process will deliver the medicine over an extended period and may have treatment benefits.
The market for an anti-allergy lens is estimated to be over 50 million users in the US, Europe and Japan. Currently when contact lens wearers encounter seasonal allergy, they have limited options for controlling inflammation and itching. Most users resort to eye drop medications and temporarily stop wearing contact lenses. A lens that includes an anti-allergy medication will come as a relief to millions of contact lens users.
The patented controlled release Glint prototype lens is in the initial stages of development and the company expects to conduct safety clinical studies in the coming months.
Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include eye infections and corneal abrasions, glaucoma, post-surgical ocular inflammation, allergic conjunctivitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The Glint technology has the potential to increase drug efficacy and improve patient compliance.
# # #